Compared with pioglitazone and fenofibrate, saroglitazar improved steatosis, fibrosis, and NASH to a greater extent by influencing serum inflammatory cytokines and adiponectin levels in rats fed a high-fat diet [155]. Here, ADIPOQ is linked to metabolic dysfunction-associated steatohepatitis.